上海市高血压研究所于1958年成立，是一所集流行病学、临床诊治、发病机制和社区防治研究为一体的市属专业机构。研究所现设细胞与分子生物学研究室、流行病学研究室、血管检测中心、社区高血压防治中心，以及临床测试实验室、实验动物房等分支机构。
研究所是“医学基因组学国家重点实验室”成员单位，设有“上海市高血压重点实验室”，参与建设国家重大科学设施“国家转化医学研究中心”，是教育部国家重点学科（心血管内科学）、上海交通大学医学院心血管内科专业博士和硕士研究生招生单位。目前，研究重点为高血压相关基因、血管“重塑”机制和血管干祖细胞、流行病学、血管结构与功能检测以及继发性高血压筛查、高血压靶器官损伤早期检测、难治性高血压治疗。
瑞金医院高血压科与研究所实行所科合一管理体制，本部院区设有35张床位，北部院区设有25张床位，在两个院区均设立全日高血压专科门诊，提供急、危、重症或复杂高血压诊治服务。
所长和科主任为王继光教授，现任中国高血压联盟主席、HOPE Asia副主席、前国际高血压学会执委、亚太高血压学会主席、亚洲动脉学会主席。担任Journal of Clinical Hypertension主编、Hypertension副主编、Hypertension Research 副主编、Pulse共同主编、《中华心血管病杂志》副总编等。王继光教授长期从事高血压诊治与科研工作，在高血压人群研究及临床研究方面取得丰硕成果，获得华夏医学科技二等奖。
研究所开展肾素、儿茶酚胺等高血压专业特色检测服务，以及动态血压监测、心脏超声、颈动脉超声、大动脉弹性功能、内皮功能、自主神经功能、压力反射敏感性等专业检测服务。
研究所与澳大利亚、比利时、加拿大、法国、日本、英国、美国等多个国家的科研机构或科学家建立了良好的合作关系。联合申报国际合作科研项目，共同开展高血压及其并发症相关科学研究。
Shanghai Institute of Hypertension
The Shanghai Institute of Hypertension was established in the year of 1958 by the municipal government of Shanghai, and is devoted to epidemiological, clinical, pathophysiological, and community studies on hypertension. The Institute is currently composed of Laboratory of Cellular and Molecular Biology, Centre for Epidemiological Studies and Clinical Trials, Centre for Vascular Evaluations, Centre for Hypertension Management and Prevention in Community, Clinical Laboratory, and Laboratory of Experimental Animals.
The Institute is a member of the State Key Laboratory of Medical Genomics and has the Shanghai Key Laboratory of Hypertension. The institute participates in the construction of the national major scientific infrastructure "National Research Centre for Translational Medicine" and belongs to state key discipline (cardiovascular internal medicine) of the Ministry of Education. The Institute also provides educational opportunities for graduate students of doctors and masters in cardiovascular medicine. The current research in the Institute focuses on human genetics in hypertension, vascular remodeling and vascular stem and progenitor cells, clinical trials and epidemiology, vascular structure and function, screening of secondary hypertension, early detection of target organ damage, and treatment of refractory hypertension.
The Department of Hypertension of Ruijin Hospital is the clinical wing of the Institute, with 35 and 25 beds in the main and north campuses, respectively. In both campuses, there is full-time outpatient clinic service for the treatment of hypertension, particularly acute, critical, severe or complicated hypertension.
Professor Ji-Guang Wang is director of the Shanghai Institute of Hypertension and director of the Department of Hypertension. He is the president of the Chinese Hypertension League, deputy president of the HOPE Asia Network, a former executive council member of the International Society of Hypertension, past president of the Asian-Pacific Society of Hypertension, and past president of the Pulse of Asia Society. He serves on the editorial board of several national and international journals in the field of hypertension and cardiovascular disease, such as the Journal of Clinical Hypertension (Editor-in-Chief), Hypertension (Associate Editor), Hypertension Research (Associate Editor), Pulse (Co-Editor), and Chinese Journal of Cardiology (Associate Editor). Professor Wang has published more than 500 articles in the international literature and lectured extensively in international and national scientific conferences. The research work of his team was awarded a second prize of Huaxia Medical Scientific and Technological Awards in 2015.
The Institute also provides service for several clinical and laboratory measurements in relation to hypertension, such as plasma renin activity, urinary catecholamines, ambulatory blood pressure monitoring, echocardiography, carotid ultrasonography, arterial stiffness, endothelial function, autonomous nervous function and baroreflex sensitivity.
The Institute has developed collaborative partnership with scientists and scientific institutions from several countries, such as Australia, Belgium, Canada, France, Japan, UK、and the United States of America.
